New indication expands use of Brilinta (ticagrelor) beyond cardiovascular disease to patients with mild-to-moderate stroke
9 Novembre 2020
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute
